Navigation Links
NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
Date:10/4/2011

tage clinical trials," Ms. Powers continued.  "In the trials so far, patients who received the DCVax® dendritic cell treatments lived for years longer than patients receiving standard of care (not just weeks or months longer), and without toxicity.  Building upon the original discovery of dendritic cells by Dr. Steinman, we are working to make dendritic cell treatments widely available for patients, and believe that such treatments have the potential to become a new standard of care for most cancers."

The Company's broad platform technology for dendritic cell-based vaccines is currently being tested in an ongoing 240-patient Phase II clinical trial for newly diagnosed Glioblastoma multiforme ("GBM") -- the most aggressive and lethal form of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.

Dr. Maida joined the Company in June, 2011, as Chief Operating Officer ("COO"), bringing more than 20 years' experience in building oncology companies, with expertise in the business, financial, clinical and regulatory aspects of oncology products, as well as the underlying science.  Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings for oncology companies.  Among these experiences, he served as CEO of CancerVax, an early leader in cancer vaccines.  In that role, he raised the company's first $30 million of funding, and was responsible for conducting multi-hundred patient, multi-center clinical trials with the company's cancer vaccines.  Prior to joining NORTHWEST BIO, Dr. Maida was serving as Global Head of Oncology for a leading contract research organiz
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
2. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
3. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
4. Northwest Biotherapeutics Announces Change and Expansion of Management Team
5. Northwest Biotherapeutics Announces Series of Financing Arrangements
6. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
7. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
8. Northwest Biotherapeutics Addresses Recent Market Activity
9. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
10. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
11. BioSpace Highlights the Northwests Growing Life Science Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... Correct the Record and Provide Accurate Information to ... ... 20 VaxGen,Inc. (Pink Sheets: VXGN), (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), ... biotechnologies announced on,November 12, 2007 that their respective Boards of Directors ...
... ExL Pharma is pleased to announce the,fall ... leading issues that are,impacting the pharmaceutical industry today. ... networking opportunities for Clinical,Marketing, R&D, and Medical Affairs ... technology companies. Listed below are details on ...
... Tools Experience to the Leader in ... Cellular Bioenergetic Profiling, N. ... tools for real-time measurement of cellular,bioenergetics in microplates, announced today ... the company,s Board of,Directors. In this position, Keegan will apply ...
Cached Biology Technology:VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2
(Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
(Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
(Date:7/10/2014)... -- Acuity Market Intelligence today released forecasts from "The Global ... global market for National Electronic ID (eID) programs will generate ... time, the number of National eID cards in circulation will ... , with its vast population, will dominate the market ... Europe trails a distant second at ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... Through an innovative feat of plant biotechnology and vaccine ... University have successfully turned tobacco plants into vaccine production ... vaccine elicits a protective immune response in guinea pigs. ... the future development of a new vaccine for human ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
... Just as baby mammals depend on their mothers' milk, ... themselves by stripping off and eating the fat-rich outer ... team of researchers that includes University of Michigan biologist ... issue (April 13) of the journal Nature. , Hatchlings ...
Cached Biology News:Plant-derived vaccines safeguard against deadly plague 2Plant-derived vaccines safeguard against deadly plague 3Do plants have the potential to vaccinate against HIV? 2African amphibians make extreme parental sacrifice: The skin off their backs 2African amphibians make extreme parental sacrifice: The skin off their backs 3
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: